XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Additional Paid-in Capital
Accumulated Deficit
Accumulated other comprehensive income
Noncontrolling interests
Series A
Common Stock
Series B
Common Stock
Balance at Jul. 31, 2020 $ 130,528 $ 129,136 $ (16,255) $ 3,762 $ 13,728 $ 8 $ 149
Balance (in Shares) at Jul. 31, 2020           787,163 15,028,536
Net loss (24,766) (24,544) (222)
Stock-based compensation 6,633 6,623 $ 10
Stock-based compensation (in Shares)           965,938
Shares issued - Investment in Altira 8,501 8,498 $ 3
Shares issued - Investment in Altira (in Shares)           280,323
Shares issued - Securities Purchase Agreement 13,000 12,994 $ 6
Shares issued - Securities Purchase Agreement (in Shares)           567,437
Shares withheld for payroll taxes (185) (185)
Shares withheld for payroll taxes (in Shares)           (7,214)
Warrants exercised 2,000 1,999 $ 1
Warrants exercised (in Shares)           87,298
Stock options exercised 71 71
Stock options exercised (in Shares)           14,546
Capital contribution for noncontrolling interest 912 912
Foreign currency translation adjustment 10 10
Balance at Jul. 31, 2021 136,704 159,136 (40,799) 3,772 14,418 $ 8 $ 169
Balance (in Shares) at Jul. 31, 2021           787,163 16,936,864
Net loss (142,377) (124,658) (17,719)
Stock-based compensation 18,061 18,045 $ 16
Stock-based compensation (in Shares)           1,533,311
Forfeiture of restricted stock (18,978) (18,969) $ (9)
Forfeiture of restricted stock (in Shares)           (943,305)
Common stock sold to investors 99,170 99,142 $ 28
Common stock sold to investors (in Shares)           2,833,425
Transaction costs incurred in connection with sale of common stock (6,228) (6,228)
Acquisition of additional ownership interest in LipoMedix 8 (8)
Common stock sold to related party 10,997 10,964 $ 33
Common stock sold to related party (in Shares)           3,338,307
Shares withheld for payroll taxes (75) (75)
Shares withheld for payroll taxes (in Shares)           (10,638)
Unrealized loss on available-for-sale securities (63) (63)
Foreign currency translation adjustment (5) (5)
Balance at Jul. 31, 2022 $ 97,206 $ 262,023 $ (165,457) $ 3,704 $ (3,309) $ 8 $ 237
Balance (in Shares) at Jul. 31, 2022           787,163 23,687,964